Innocoll is dedicated to making better happen — finding solutions to help patients reduce pain associated with surgeries and to treat limb-threatening infections.
Our proprietary, biocompatible, and biodegradable collagen-based products are engineered for targeted use.
Applied locally to wound and/or surgery sites, they are designed to provide a range of treatment benefits.
Our late-stage product pipeline is focused on addressing a number of significant unmet medical needs:
INL-001, bioresorbable bupivacaine HCI collagen-matrix implants (Phase III completed), in development for postsurgical analgesia;
INL-002, a gentamicin collagen-matrix patch, in development for the treatment of diabetic foot infections (Phase III completed);
INL-003, a bioresorbable collagen film surgical adhesion barrier (approved ex-US), in development for the prevention of postsurgical adhesions.